MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed/Refractory FLT3-mutant Acute Myeloid Leukemia Patients
ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches
Robust, rapid and durable efficacy - ORR 81%, of which 64% are CR/CRi68% of CR/CRi lasting more than 6 monthsLongest remission + 3 yearsIadademstat and azacitidine combination shows a good safety...
Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different hematological and solid tumors MADRID, Spain and BOSTON, July 19, 2022 (GLOBE...
81% of evaluable patients achieved an objective responseDeep responses: 64% are CR/CRi, of which 86% achieved transfusion independenceRapid and durable responses: 91% by end of cycle 2, with 64% of...
MADRID, Spain and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s clinical stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer (SCLC). Iadademstat is an oral, highly potent and selective inhibitor of the epigenetic enzyme LSD1, a chromatin remodeler that interacts with a variety of transcription factors involved in SCLC, other solid tumors and hematological cancers such as acute myeloid leukemia (AML).
MADRID, Spain and CAMBRIDGE, Mass., June 07, 2022 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
In combination with gilteritinibPrimary objectives: to assess safety, tolerability and RP2DSecondary objectives: to assess efficacy MADRID, Spain and CAMBRIDGE, Mass., March 21, 2022 (GLOBE...
ORYZON Genomics, a public clinical-stage biopharmaceutical company, announced that the US Food and Drug Administration (FDA) have granted Orphan Drug Designation to the company’s first-in-class LSD1 inhibitor iadademstat for the treatment of patients with acute myeloid leukemia (AML).